---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-23-000045"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:11:10.527916+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics Q3 net loss $23.0M; cash $144.3M; advances BDTX-1535 and BDTX-4933 trials

## Summary
- Net loss $23.0M vs $21.7M in Q3 2022; R&D $16.2M, G&A $7.9M (includes CEO transition costs).
- Cash, cash equivalents, and investments $144.3M at Sep 30, 2023; expected to fund operations into H1 2025.
- BDTX-1535 Phase 1 expansion cohorts enrolling; initial NSCLC expansion data expected 2024; GBM dose escalation data later 2023.
- BDTX-4933 Phase 1 trial dosed first patient; targeting KRAS, NRAS, BRAF mutations; dose escalation ongoing.
- Mark Velleca appointed President and CEO in September 2023.

## SEC filing metadata
- accession: 0001701541-23-000045
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000045/0001701541-23-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000045/bdtx-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-23-000045
- JSON: https://secwatch.observer/filing/0001701541-23-000045.json
- Plain text: https://secwatch.observer/filing/0001701541-23-000045.txt

## Key facts
- Earnings Releases
  Black Diamond Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 6, 2023, Black Diamond Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000045/0001701541-23-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.